Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. METHODS: In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes. RESULTS: Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups. CONCLUSIONS: In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but subgroup analyses suggested a benefit of oral insulin in individuals with the highest titres of insulin auto-antibodies.142,143”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“The Diabetes Prevention Trial—Type 1, tested whether oral or parental insulin prevented the development of type 1 diabetes in people who were autoantibody positive. Neither approach reduced diabetes development,”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“If one islet autoantibody is found, the test should be repeated and the other autoantibodies should be assayed because the risk of type 1 diabetes increases if two or more autoantibodies are positive (443).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [443]
In the citing paper
“Subcutaneously or intranasally delivered insulin was found to have no preventive effects.39,48”
From The future of type 1 diabetes therapy (2025) · cites this paper as [48]
In the citing paper
“Risk can be assessed by islet cell autoantibodies alone, without the need for evaluating endogenous insulin reserves, as was done for the U.S. DPT-1 trial (306).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [306]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
Epstein, F. H., Atkinson, M. A., & Maclaren, N. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312107 · Cited by 1,078
Verge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Cognitive Deficits in Adolescents Who Developed Diabetes Early in Life
Ryan, C., Vega, A., & Drash, A. (1985) · Pediatrics · doi:10.1542/peds.75.5.921 · Cited by 413
Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy
Atkinson, M. A., Maclaren, N. K., & Luchetta, R. (1990) · Diabetes · doi:10.2337/diab.39.8.933 · Cited by 299
Insulin prophylaxis in individuals at high risk of type 1 diabetes
Keller, R. J., Jackson, R. A., Eisenbarth, G. S., & Eisenbarth, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91215-8 · Cited by 298
Pugliese, A., Gianani, R., Moromisato, R., Awdeh, Z. L., Alper, C. A., Erlich, H. A., Jackson, R. A., & Eisenbarth, G. S. (1995) · Diabetes · doi:10.2337/diab.44.6.608 · Cited by 207
Gotfredsen, C. F., Buschard, K., & Frandsen, E. K. (1985) · Diabetologia · doi:10.1007/bf00703140 · Cited by 205
Vardi, P., Dib, S. A., Tuttleman, M., Connelly, J. E., Grinbergs, M., Radizabeh, A., Riley, W. J., Maclaren, N. K., Eisenbarth, G. S., & Soeldner, J. S. (1987) · Diabetes · doi:10.2337/diab.36.11.1286 · Cited by 192
Attentional Functioning in Children and Adolescents With IDDM
Rovet, J., & Alvarez, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.803 · Cited by 153
Cited by
Items 301–400 of 832
The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS)
Groups, T. D. T. 1. T. A. D. P. T.-T. 1. S., Sosenko, J. M., Skyler, J. S., & Palmer, J. P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0626-1 · Cited by 31
Novel targeted therapies for autoimmunity
Clair, E. W. S. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.09.008 · Cited by 33
Toward Precise Forecasting of Autoimmune Endocrinopathy
Pearce, S. H. S., & Leech, N. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032142 · Cited by 31
Immunological mechanisms associated with long‐term remission of human type 1 diabetes
Karges, B., Durinovic‐Belló, I., Heinze, E., Debatin, K., Boehm, B. O., & Karges, W. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.600 · Cited by 31
Why Can’t We Prevent Type 1 Diabetes?
Schatz, D., Gale, E. A., & Atkinson, M. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3326 · Cited by 33
Therapy of autoimmune diseases: clinical trials and new biologics
Nepom, G. T. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00397-7 · Cited by 31
Siljander, H., Härkönen, T., Hermann, R., Simell, S., Hekkala, A., Salonsaari, R., Simell, T., Simell, O., Ilonen, J., Veijola, R., et al. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.998 · Cited by 30
Rapini, N., Schiaffini, R., & Fierabracci, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062103 · Cited by 35
Pozzilli, P., Crinò, A., Schiaffini, R., Manfrini, S., Fioriti, E., Coppolino, G., Pitocco, D., Visalli, N., Corbi, S., Spera, S., et al. (2003) · Diabetes Technology & Therapeutics · doi:10.1089/152091503322641006 · Cited by 32
Skak, K., Gotfredsen, C. F., Lundsgaard, D., Hansen, J. B., Sturis, J., & Markholst, H. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1089 · Cited by 30
Type 1 diabetes mellitus prevention: present and future
Henriques, F. L., Buckle, I., & Forbes, J. M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01128-6 · Cited by 36
Cabrera‐Rode, E., Molina, G., Arranz, C., Vera, M., González, P., Suárez, R., Prieto, M., Padron, S. A., León, R., Tillán, J., et al. (2006) · Autoimmunity · doi:10.1080/08916930600738383 · Cited by 31
Inducing immune tolerance: a focus on Type 1 diabetes mellitus
Xu, D., Prasad, S., & Miller, S. D. (2013) · Diabetes Management · doi:10.2217/dmt.13.36 · Cited by 32
Immunotherapy of insulin-dependent diabetes mellitus
Masteller, E. L., & Bluestone, J. A. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00375-8 · Cited by 29
Clinical Immunologic Interventions for the Treatment of Type 1 Diabetes
Chatenoud, L., Warncke, K., & Ziegler, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007716 · Cited by 33
Quantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi, A., Carr, A. L. J., Martino, M., Taylor, P., Senior, P. A., & Dayan, C. M. (2023) · Diabetologia · doi:10.1007/s00125-023-06011-5 · Cited by 32
Papaefstathiou, E., Moysidis, K., Sarafis, P., Ioannidis, E., & Konstantinos Hatzimouratidis, A. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.11.009 · Cited by 28
Johnson, S. B., Baughcum, A. E., Hood, K. K., Rafkin‐Mervis, L., Schatz, D., & for the DPT-1 Study Group (2007) · Diabetes Care · doi:10.2337/dc06-2422 · Cited by 28
The Role of Immunomodulation Therapy in Autoimmune Diabetes
Ludvigsson, J. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300213 · Cited by 32
Sosenko, J. M., Geyer, S. M., Skyler, J. S., Rafkin, L. E., Ismail, H. M., Libman, I. M., Liu, Y., DiMeglio, L. A., Evans‐Molina, C., & Palmer, J. P. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12609 · Cited by 30
Overview of Prevention and Intervention Trials for Type 1 Diabetes
Daaboul, J. J., & Schatz, D. (2003) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1027308310837 · Cited by 30
Prevention Strategies for Type 1 Diabetes Mellitus: Current Status and Future Directions
Winter, W. E., & Schatz, D. (2003) · BioDrugs · doi:10.2165/00063030-200317010-00004 · Cited by 29
Therapies to Preserve β-Cell Function in Type 1 Diabetes
Ludvigsson, J. (2015) · Drugs · doi:10.1007/s40265-015-0511-x · Cited by 30
Type 1 diabetes: where are we in 2017?
Copenhaver, M. M., & Hoffman, R. P. (2017) · Translational Pediatrics · doi:10.21037/tp.2017.09.09 · Cited by 34
Diabetes type 1: Can it be treated as an autoimmune disorder?
Vallianou, N. G., Stratigou, T., Geladari, E. V., Tessier, C. M., Mantzoros, C. S., & Dalamaga, Μ. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09642-4 · Cited by 35
Chapter 2 CD3 Antibodies as Unique Tools to Restore Self-Tolerance in Established Autoimmunity
You, S., Candon, S., Kuhn, C., Bach, J., & Chatenoud, L. (2008) · Advances in immunology · doi:10.1016/s0065-2776(08)00802-x · Cited by 28
Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial
Chase, H. P., Leschek, E., Rafkin‐Mervis, L., Krause-Steinrauf, H. J., Chritton, S., Asare, S. M., Adams, S., Skyler, J. S., Clare-Salzler, M. J., & A. T. T. 1. D. T. N. S. G. (2009) · ICAN Infant Child & Adolescent Nutrition · doi:10.1177/1941406409333466 · Cited by 27
The Role of C-Peptide Levels in Screening for Latent Autoimmune Diabetes in Adults
Bell, D. S. H., & Ovalle, F. (2004) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000102372.28723.2b · Cited by 29
Administration of metrnl delays the onset of diabetes in non-obese diabetic mice
Yao, Z., Lin, P., Wang, C., Wang, K., & Sun, Y. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0351 · Cited by 29
Reducing the Risk of Developing Diabetes
Ransom, T. P. P., Goldenberg, R., Mikalachki, A., Prebtani, A. P. H., & Punthakee, Z. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.013 · Cited by 43
Chaillous, L., Bouhanick, B., Kerlan, V., Mathieu, E., Lecomte, P., Ducluzeau, P., Delamaire, M., Sonnet, E., Maugendre, D., Maréchaud, R., et al. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.07.004 · Cited by 28
New potential treatments for protection of pancreatic B‐cell function in Type 1 diabetes
Cernea, S., & Pozzilli, P. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02556.x · Cited by 30
Latent autoimmune diabetes in adults
Gilliam, L. K., & Palmer, J. P. (2006) · Insulin · doi:10.1016/s1557-0843(06)80021-7 · Cited by 28
Defining populations at risk of rheumatoid arthritis: the first steps to prevention
Hunt, L. H., & Emery, P. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.82 · Cited by 30
Felton, J. L., Griffin, K., Oram, R. A., Speake, C., Long, S. A., Önengüt-Gümüşcü, S., Rich, S. S., Monaco, G. S. F., Evans‐Molina, C., DiMeglio, L. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00357-y · Cited by 33
Ludvigsson, J. (2008) · Diabetologia · doi:10.1007/s00125-008-1211-9 · Cited by 26
Current Concepts and Controversies in Prevention and Treatment of Diabetic Ketoacidosis in Children
Rewers, A. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0307-2 · Cited by 28
Use of Anti‐CD3 Monoclonal Antibody to Induce Immune Regulation in Type 1 Diabetes
Bisikirska, B. C., & Herold, K. C. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1337.001 · Cited by 26
Banga, J. P., Nielsen, C. H., Gilbert, J. A., Fassi, D. E., & Hegedűs, L. D. (2008) · Thyroid · doi:10.1089/thy.2007.0406 · Cited by 26
In utero undernutrition reduces diabetes incidence in non-obese diabetic mice
Oge, A., ISGANAITIS, E. M., Jimenez-Chillaron, J., Reamer, C., Faucette, R., Barry, K., Przybyla, R., & Patti, M. (2007) · Diabetologia · doi:10.1007/s00125-007-0617-0 · Cited by 27
Thrower, S., & Bingley, P. J. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr020 · Cited by 30
Enumerating autoreactive T cells in peripheral blood: a big step in diabetes prediction
Eisenbarth, G. S., & Kotzin, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17621 · Cited by 26
Monetini, L., Cavallo, M. G., Sarugeri, E., Sentinelli, F., Stefanini, L., Bosi, E., Thorpe, R., Pozzilli, P., & the Immunotherapy Diabetes (IMDIAB) group (2004) · Diabetologia · doi:10.1007/s00125-004-1521-5 · Cited by 26
SERREZE, D. V., & Chen, Y. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.012 · Cited by 26
Hawa, M. I., Bonfanti, R., Valeri, C., Castelli, M. D., Beyan, H., & Leslie, R. D. G. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1415 · Cited by 28
Making progress: preserving beta cells in type 1 diabetes
GALLAGHER, M. P., Goland, R., & Greenbaum, C. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06321.x · Cited by 30
Couri, C. E. B., Foss, M. C., & Voltarelli, J. C. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006001000002 · Cited by 30
Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes
Simmons, K. M., Gottlieb, P. A., & Michels, A. W. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0793-8 · Cited by 28
Pancreatic islet reserve in type 1 diabetes
Flatt, A. J., Greenbaum, C. J., Shaw, J., & Rickels, M. R. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14572 · Cited by 28
The Belgian Diabetes Registry, Vandemeulebroucke, E., Keymeulen, B., Decochez, K., Weets, I., Block, C. E. M. D., Féry, F., de Velde, U. V., Vermeulen, I., Pauw, P. E. M. D., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1569-3 · Cited by 29
Antigen-Specific Induction of Regulatory T Cells for Type 1 Diabetes Therapy
Filippi, C. M., Bresson, D., & von Herrath, M. (2005) · International Reviews of Immunology · doi:10.1080/08830180500371116 · Cited by 25
The History of Diabetes Mellitus
Tattersall, R. B., & Matthews, D. R. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch1 · Cited by 32
Immunomodulation with human recombinant autoantigens
Lernmark, Å., & Agardh, C.-D. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.015 · Cited by 24
Evans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06462-y · Cited by 35
Possible heterogeneity of initial pancreatic islet beta‐cell autoimmunity heralding type 1 diabetes
Lernmark, Å., Akolkar, B., Hagopian, W., Krischer, J. P., McIndoe, R., Rewers, M., Toppari, J., Vehik, K., Ziegler, A., & The TEDDY Study Group (2023) · Journal of Internal Medicine · doi:10.1111/joim.13648 · Cited by 32
Reducing the Risk of Developing Diabetes
Prebtani, A. P. H., BAJAJ, H. S., Goldenberg, R., & Mullan, Y. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.033 · Cited by 36
Immune intervention at diagnosis ? should we treat children to preserve beta-cell function?
Ludvigsson, J. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00299.x · Cited by 24
Tolerance-inducing medicines in autoimmunity: rheumatology and beyond
Stanway, J. A., & Isaacs, J. D. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30100-4 · Cited by 23
Chatenoud, L., You, S., Okada, H., Kuhn, C., Michaud, B., & Bach, J. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04125.x · Cited by 27
Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes
Greenbaum, C. J., Lord, S. M., & VanBuecken, D. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0932-x · Cited by 25
Immunotherapy for type 1 diabetes
Allen, L. A., & Dayan, C. M. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldab027 · Cited by 24
Geenen, V., & Brilot, F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03149.x · Cited by 18
Targeted immune interventions for type 1 diabetes
Rigby, M. R., & Ehlers, M. R. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000075 · Cited by 25
Johnson, S. B., Baughcum, A. E., Rafkin‐Mervis, L., Schatz, D., & DPT-1 Study Group (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00463.x · Cited by 23
Self-citationGerstein, H. C., & Rosenstock, J. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.002 · Cited by 25
Cellular Therapy for Type 1 Diabetes: Has the Time Come?
Skyler, J. S. (2007) · JAMA · doi:10.1001/jama.297.14.1599 · Cited by 23
Emerging Immunotherapies for Disease Modification of Type 1 Diabetes
Foster, T. P., Bruggeman, B., & Haller, M. J. (2025) · Drugs · doi:10.1007/s40265-025-02150-8 · Cited by 24
Gandhi, G. Y., Murad, M. H., Flynn, D. N., Elamin, M. B., Erwin, P. J., Montori, V. M., & Kudva, Y. C. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03179.x · Cited by 23
The Classification of Diabetes Mellitus: A Conceptual Framework
Ize-Ludlow, D., & Sperling, M. A. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.07.001 · Cited by 27
Non-antigenic and antigenic interventions in type 1 diabetes
Rydén, A. K., Wesley, J. D., Coppieters, K. T., & von Herrath, M. G. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26890 · Cited by 26
REDONDO, M. J., Fain, P. R., Krischer, J. P., Yu, L., Cuthbertson, D. D., Winter, W. E., & Eisenbarth, G. S. (2004) · Journal of Autoimmunity · doi:10.1016/j.jaut.2004.07.001 · Cited by 22
Thymus and type 1 diabetes: An update
Geenen, V. G. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.023 · Cited by 23
Krishnamurthy, B., Selck, C., Chee, J., Jhala, G., & Kay, T. W. H. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.03.018 · Cited by 24
Sims, E. K., & DiMeglio, L. A. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.010 · Cited by 23
Autoantibodies in Type 1 diabetes
Schmidt, K. D., Valeri, C., & Leslie, R. D. G. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.11.017 · Cited by 29
Stipančić, G., Šepec, M. P., Sabolić, L. L. G., Radica, A., Škrabić, V., Severinski, S., & Tiljak, M. K. (2011) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2011.231 · Cited by 22
Immunotherapy of type 1 diabetes
Li, L., Yi, Z., Tisch, R., & Wang, B. (2008) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-008-0025-2 · Cited by 22
Couper, J., & Donaghue, K. C. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2006.00225.x · Cited by 24
Ziegler, A., Achenbach, P., Weiß, A., Berner, R., Casteels, K., Larsson, H. E., Haupt, F., Hommel, A., Jacobs, A., Kordonouri, O., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01726-x · Cited by 24
Ferrannini, E., Mari, A., Monaco, G. S. F., Skyler, J. S., & Evans‐Molina, C. (2022) · Diabetologia · doi:10.1007/s00125-022-05836-w · Cited by 21
Ackun‐Farmmer, M. A., & Jewell, C. M. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200135 · Cited by 21
Fukushima, K., Abiru, N., Nagayama, Y., Kobayashi, M., Satoh, T., Nakahara, M., Kawasaki, E., Yamasaki, H., Ueha, S., Matsushima, K., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.12.191 · Cited by 21
T-cell epitopes in type 1 diabetes
Panagiotopoulos, C., Trudeau, J. D., & Tan, R. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0062-0 · Cited by 24
Hao, W., Wookwyk, A., Beam, C. A., Bahnson, H. T., Palmer, J. P., & Greenbaum, C. J. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01713 · Cited by 21
Nelson, P. W., Smith, N. R., Ciupe, S. M., Zou, W., Omenn, G. S., & Pietropaolo, M. (2009) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2009.6.753 · Cited by 21
The History of Diabetes Mellitus
Tattersall, R. B. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch1 · Cited by 30
The History of Diabetes Mellitus
Tattersall, R. B. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch1 · Cited by 27
Gorus, F., Keymeulen, B., Veld, P. I. '., & PIPELEERS, D. G. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.856757 · Cited by 23
A perspective on treating type 1 diabetes mellitus before insulin is needed
Tatović, D., Narendran, P., & Dayan, C. M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00816-5 · Cited by 34
Zhao, L. P., Papadopoulos, G. K., Skyler, J. S., Parikh, H. M., Kwok, W. W., Bondinas, G. P., Moustakas, A. K., Wang, R., Pyo, C.-W., Nelson, W. C., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0573 · Cited by 20
Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics
You, S., & Chatenoud, L. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3139-2_8 · Cited by 23
Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all
Koufakis, T., Katsiki, N., Zebekakis, P. E., Dimitriadis, G., & Kotsa, K. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12982 · Cited by 20
Etiology of Autoimmune Islet Disease: Timing Is Everything
Lernmark, Å. (2021) · Diabetes · doi:10.2337/dbi18-0034 · Cited by 27
Harrison, L. C. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101288 · Cited by 22
Tissue glycogen content and glucose intolerance
Kasuga, M., Ogawa, W., & Ohara, T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18526 · Cited by 21
Islet Autoantibody Seroconversion in the DPT-1 Study
Vehik, K., Haller, M. J., Beam, C. A., Schatz, D., Wherrett, D. K., Sosenko, J. M., Krischer, J. P., & DPT-1 Study Group (2011) · Diabetes Care · doi:10.2337/dc10-1494 · Cited by 25
Self-citationAntiviral treatment of Coxsackie B virus infection in human pancreatic islets
Berg, A., Olsson, A., Korsgren, O., & Frisk, G. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.12.001 · Cited by 22
Jacobsen, L. M., Felton, J. L., Nathan, B. M., Speake, C., Krischer, J. P., & Herold, K. C. (2025) · Diabetes Care · doi:10.2337/dc24-2908 · Cited by 26
Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies
Maziarz, M., Hagopian, W., Palmer, J. P., Sanjeevi, C. B., Kockum, I. S., Breslow, N. E., Lernmark, Å., Graham, J., MacNeney, B., Arnqvist, H. J., et al. (2015) · Genes and Immunity · doi:10.1038/gene.2015.43 · Cited by 23
Mital, S., & Nguyen, H. V. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00962-y · Cited by 22
Metadata
- Authors
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Affiliations
- University of Miami (US)
- Corresponding author
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-30
- Volume
- 346
- Issue
- 22
- Pages
- 1685-1691
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W614574849
- Cited by
- 836
- References
- 30
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 27 · 2016: 26 · 2015: 34 · 2014: 30 · 2013: 38 · 2012: 42
- FWCI
- 28.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, insulin therapy, diabetes prevention, relatives of diabetic patients, islet cell antibodies, ultralente insulin, continuous intravenous insulin infusion, glucose tolerance, hypoglycemia, disease progression
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Glucose Tolerance Test, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Islets of Langerhans, Male, Middle Aged, Risk Factors, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.